Omar Abdel-Wahab Selected Research

Agammaglobulinaemia Tyrosine Kinase

2/2024	Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.
1/2022	Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.
1/2021	Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Omar Abdel-Wahab Research Topics

Disease

118	Neoplasms (Cancer) 04/2024 - 01/2004
34	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 05/2024 - 04/2010
28	Leukemia 12/2023 - 03/2010
21	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 05/2024 - 11/2013
14	Histiocytosis 12/2023 - 01/2016
10	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 09/2013
7	Melanoma (Melanoma, Malignant) 01/2018 - 08/2004
6	Erdheim-Chester Disease 01/2020 - 10/2016
5	Primary Myelofibrosis (Myelosclerosis) 10/2023 - 04/2010
5	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2023 - 10/2012
5	Disease Progression 01/2022 - 03/2013
5	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 01/2022 - 06/2013
4	Hairy Cell Leukemia 10/2023 - 10/2015
4	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2022 - 01/2020
3	Uveal melanoma 01/2022 - 09/2012
3	Breast Neoplasms (Breast Cancer) 01/2022 - 01/2018
3	Residual Neoplasm 12/2021 - 02/2013
3	Hypersensitivity (Allergy) 01/2020 - 06/2013
3	Langerhans-Cell Histiocytosis (Histiocytosis, Langerhans Cell) 03/2018 - 01/2016
3	Polycythemia Vera 07/2015 - 10/2010
3	Splenomegaly 03/2015 - 09/2012
2	Mitochondrial Diseases (Mitochondrial Disease) 05/2024 - 04/2024
2	Exanthema (Rash) 12/2022 - 10/2015
2	Fever (Fevers) 12/2022 - 01/2020
2	Inflammation (Inflammations) 01/2022 - 12/2018
2	Anemia 01/2022 - 01/2019
2	Neuroblastoma 01/2021 - 01/2016
2	Fibrosis (Cirrhosis) 01/2020 - 12/2015
2	Carcinogenesis 10/2019 - 03/2019
2	Non-Langerhans-Cell Histiocytosis (Histiocytosis, Non Langerhans Cell) 01/2019 - 01/2017
2	T-Cell Lymphoma (Lymphoma, T Cell) 01/2017 - 10/2012
2	Juvenile Myelomonocytic Leukemia 01/2017 - 06/2013
2	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 03/2013 - 02/2011
2	Glioma (Gliomas) 02/2012 - 03/2010
2	Thrombocytosis (Thrombocythemia) 10/2010 - 04/2010
1	Alzheimer Disease (Alzheimer's Disease) 01/2024

Drug/Important Bio-Agent (IBA)

36	RNA Splicing FactorsIBA 05/2024 - 05/2012
27	Proteins (Proteins, Gene)FDA Link 05/2024 - 08/2004
20	Phosphotransferases (Kinase)IBA 12/2023 - 04/2010
17	DNA (Deoxyribonucleic Acid)IBA 01/2024 - 12/2010
11	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 11/2023 - 05/2014
9	RNA (Ribonucleic Acid)IBA 01/2023 - 04/2005
8	Messenger RNA (mRNA)IBA 05/2024 - 01/2017
8	VemurafenibIBA 10/2023 - 12/2012
7	Histones (Histone)IBA 01/2021 - 01/2012
7	alpha-hydroxyglutarateIBA 03/2014 - 03/2010
6	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 10/2023 - 03/2010
5	Mitogen-Activated Protein KinasesIBA 01/2021 - 01/2016
4	ChromatinIBA 01/2022 - 09/2012
4	Protein Isoforms (Isoforms)IBA 01/2022 - 01/2017
4	CytosineIBA 10/2020 - 10/2012
4	EnzymesIBA 01/2017 - 09/2004
4	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2013 - 02/2011
3	Agammaglobulinaemia Tyrosine KinaseIBA 02/2024 - 01/2021
3	venetoclaxIBA 01/2023 - 01/2021
3	Arginine (L-Arginine)FDA Link 01/2023 - 05/2012
3	MethyltransferasesIBA 01/2023 - 01/2018
3	Biomarkers (Surrogate Marker)IBA 12/2021 - 06/2014
3	LigandsIBA 11/2021 - 01/2018
3	cobimetinibIBA 01/2020 - 05/2014
3	acetoacetic acid (acetoacetate)IBA 01/2017 - 08/2015
3	CytokinesIBA 12/2015 - 06/2013
2	PoisonsIBA 05/2024 - 04/2024
2	Lysine (L-Lysine)FDA Link 11/2023 - 11/2015
2	obinutuzumabIBA 10/2023 - 12/2021
2	Serine (L-Serine)FDA Link 01/2023 - 05/2012
2	Thrombopoietin ReceptorsIBA 01/2023 - 09/2012
2	Chimeric Antigen ReceptorsIBA 01/2023 - 10/2022
2	Peptides (Polypeptides)IBA 01/2022 - 01/2021
2	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2021
2	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2022 - 01/2016
2	pirtobrutinibIBA 01/2022 - 01/2021
2	InterferonsIBA 01/2022 - 08/2013
2	CalreticulinIBA 01/2022 - 01/2018
2	Amino Acids FDA Link 01/2022 - 01/2020
2	Azacitidine (5 Azacytidine)FDA Link 01/2021 - 04/2013
2	RNA Splice SitesIBA 01/2021 - 01/2020
2	Decitabine FDA Link 01/2021 - 05/2015
2	CholesterolIBA 10/2020 - 02/2013
2	Interleukin-3 (Interleukin 3)IBA 01/2020 - 06/2013
2	RNA Precursors (Precursor, mRNA)IBA 01/2020 - 01/2018
2	Cell-Free Nucleic AcidsIBA 01/2019 - 12/2016
2	AnthracyclinesIBA 01/2019 - 12/2016
2	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 01/2018 - 05/2014
2	KetonesIBA 01/2017 - 01/2017
2	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2017 - 06/2013
2	ruxolitinibIBA 12/2015 - 03/2015
2	Janus Kinase InhibitorsIBA 12/2015 - 03/2015
2	Glutathione (Reduced Glutathione)IBA 09/2004 - 08/2004
2	Melphalan (Alkeran)FDA LinkGeneric 09/2004 - 08/2004
1	CohesinsIBA 01/2024
1	5-Methylcytosine (5 Methylcytosine)IBA 12/2023
1	SulfonamidesIBA 12/2023
1	N- (3- cyano- 4- methyl- 1H- indol- 7- yl)- 3- cyanobenzene- sulfonamideIBA 12/2023

Therapy/Procedure

51	Therapeutics 04/2024 - 08/2004
8	Immunotherapy 10/2022 - 01/2004
3	Drug Therapy (Chemotherapy) 12/2016 - 08/2004
2	Cell Transplantation 12/2023 - 04/2013
2	Duration of Therapy 01/2023 - 12/2021
1	Stem Cell Transplantation 11/2023